Objective To detect the expression of B cell transposition gene 3( BTG3) in pancreatic ductal adenocarcinoma( PDAC) ,and explore its relationship with postoperative recurrence and metastasis of tumor. Methods Six self-paired frozen PDAC specimens and 3 normal pancreatic tissues from the Second Hospital of Jiaxing Affiliated to Jiaxing University were collected and the expression of BTG3 was detected by qPCR. Ten normal pancreatic tissues and 52 cases of PDAC tumor and paracarcinomatous tissues from the Second Hospital of Jiaxing Affiliated to Jiaxing University were collected from June 2009 to December 2016. The expression of BTG3 and relationship among BTG3 and clinicopathological characteristics of PDAC and patients′ prognosis were detected and analyzed using immunohistochemistry.χ2 test, Kaplan-Meier method and Cox regression model were used to analyzed the data. Results The results of qPCR showed that expression level of BTG3 in PDAC ( 0. 63 ± 0. 17) was lower significantly than that in paracarcinomatous (0. 96±0. 04) and normal tissues (1. 00)(t=4. 673,5. 502;both P<0. 05). Immunohistochemistrv showed that BTG3 mainly expressed in the cytoplasm. The high expression rate of BTG3 in PDAC tumor tissues was 25. 0%( 13/52) ,which was remarkably lower than that in paracarcinomatous tissues ( 65. 4%) and normal liver tissues(7/10) (χ2=17. 120 and 5. 849,both P<0. 05) . The low expression of BTG3 in PDAC was correlated with primary tumor,and TNM stage(χ2=7. 704,P=0. 006;U=154. 000,P=0. 018,respectively). Survival analysis showed that disease free survival rate of patients with low expression of BTG3 was significantly less than that with high expression (χ2 =192. 493, P<0. 01 ) . The Cox multivariate analysis demonstrated that low expression of BTG3 was independent risk factors for disease free survival in patients with PDAC after a curative resection( RR=3. 366,95%CI:1. 040-10. 889,P=0. 043) . Conclusion BTG3 may be involved in the occurence and development of tumor,and its low expression may be associated with poor prognosis in patients with PDAC.%目的 探讨B细胞转位基因3(BTG3)在胰腺导管腺癌(PDAC)中的表达情况及其与肿瘤术后复发转移的关系.方法 收集在嘉兴市第二医院保存的6例冷冻PDAC组织和癌旁组织,以及3例正常胰腺组织,应用实时荧光定量PCR(qPCR)检测组织中BTG3的表达情况.收集2009年6月至2016年12月在嘉兴市第二医院治疗的52例PDAC患者的癌组织和癌旁组织及10例正常胰腺组织,采用免疫组织化学染色检测组织中BTG3的表达情况.通过χ2检验、Kaplan-Meier法和Cox回归模型,分析BTG3表达与PDAC患者临床病理学特征及生存预后之间的关系.结果qPCR检测结果显示,PDAC组织中BTG3表达水平(0.63±0.17)低于癌旁组织(0.96±0.04)和正常胰腺组织(1.00)(t=4.673、5.502,P值均<0.05).免疫组化检测结果显示,BTG3主要表达在细胞质中.PDAC组织中高表达BTG3的比例为25.0%(13/52),低于癌旁组织的65.4%(34/52)和正常组织的7/10(χ2=17.120,5.849;P值均<0.05).BTG3的低表达与肿瘤原发灶、TNM分期有关(χ2=7.704,P=0.006;U=154.000,P=0.018).生存分析结果发现,低表达BTG3的患者术后无病生存率小于高表达者(χ2=192.493;P<0.01).多因素分析结果表明,BTG3低表达是影响PDAC患者术后生存的独立预后因素(RR=3.366,95%CI:1.040~10.889,P=0.043).结论 BTG3可能参与PDAC的发生发展,其低表达可能与PDAC患者预后不良相关.
展开▼
